CME Information

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients with rheumatoid arthritis (RA).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe the underlying principles of innate and adaptive immunity as they contribute to understanding the mechanism of action of existing and developing immune-based therapies including anti-cytokine therapies (TNF, IL-6, IL-17, and others); T-cell- and B-cell-directed therapies; anti-checkpoint-based therapies; small molecules; anti-sense therapies; immunoregulatory-based therapies; and others.
  • Examine the underlying principles of innate and adaptive immunity as they contribute to the pathophysiologic basis of autoimmune and autoinflammatory diseases like RA.
  • Explain the clinical and immunologic progression of RA from asymptomatic autoimmunity to pre-RA and RA and relate the role of anti-citrullinated protein antibodies (ACPAs) and gene interactions to this process.
  • Assess the scientific basis for small molecule therapy of RA and allied conditions (kinase inhibitors, PPDI, and others) as well as compare and contrast data on efficacy and toxicity from these agents versus other immune-based therapies.
  • Describe recent advances in innate and adaptive immunity that contribute to the understanding of immunopathogenesis, immunodiagnostics, and selection of immune-based therapies including:
    • Genetics and epigenetics in the immunopathogenesis in autoimmune and autoinflammatory diseases.
    • The microbiome and microvirome and their relationship to the integrated immune response and immunopathogenesis.
    • The concept of immunologic checkpoint-directed therapies as a basis for cancer treatment and autoimmune and autoinflammatory complications relevant to rheumatologists.
  • Detail the challenges in interpreting safety data from studies of biologic and immune-based therapies derived from randomized trials, extension studies, and registries.
  • Develop and implement strategies to mitigate risk from biologic and immune-based therapies, including appropriate screening, critical pathways, and vaccination strategies.
  • Examine the bioengineering and regulatory basis of biosimilar drug development and critically appraise both the advantages and risks of their potential use in practice.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all planners, teachers, authors, and reviewers involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience prior to viewing content.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the Program Committee.

Preregistration is encouraged but not required. Seating to be based on arrival order; early arrival is recommended.

Copyright © Vindico Medical Education | Privacy Policy
856.994.9400 | 6900 Grove Road, Building 100 | Thorofare, New Jersey 08086
A Wyanoke Group Company